Literature DB >> 23511247

Adenoviral gene transfer corrects the ion transport defect in the sinus epithelia of a porcine CF model.

Andrea E Potash1, Tanner J Wallen, Philip H Karp, Sarah Ernst, Thomas O Moninger, Nicholas D Gansemer, David A Stoltz, Joseph Zabner, Eugene H Chang.   

Abstract

Cystic fibrosis (CF) pigs spontaneously develop sinus and lung disease resembling human CF. The CF pig presents a unique opportunity to use gene transfer to test hypotheses to further understand the pathogenesis of CF sinus disease. In this study, we investigated the ion transport defect in the CF sinus and found that CF porcine sinus epithelia lack cyclic AMP (cAMP)-stimulated anion transport. We asked whether we could restore CF transmembrane conductance regulator gene (CFTR) current in the porcine CF sinus epithelia by gene transfer. We quantified CFTR transduction using an adenovirus expressing CFTR and green fluorescent protein (GFP). We found that as little as 7% of transduced cells restored 6% of CFTR current with 17-28% of transduced cells increasing CFTR current to 50% of non-CF levels. We also found that we could overcorrect cAMP-mediated current in non-CF epithelia. Our findings indicate that CF porcine sinus epithelia lack anion transport, and a relatively small number of cells expressing CFTR are required to rescue the ion transport phenotype. These studies support the use of the CF pig as a preclinical model for future gene therapy trials in CF sinusitis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23511247      PMCID: PMC3666638          DOI: 10.1038/mt.2013.49

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  48 in total

1.  A placebo-controlled study of liposome-mediated gene transfer to the nasal epithelium of patients with cystic fibrosis.

Authors:  D R Gill; K W Southern; K A Mofford; T Seddon; L Huang; F Sorgi; A Thomson; L J MacVinish; R Ratcliff; D Bilton; D J Lane; J M Littlewood; A K Webb; P G Middleton; W H Colledge; A W Cuthbert; M J Evans; C F Higgins; S C Hyde
Journal:  Gene Ther       Date:  1997-03       Impact factor: 5.250

2.  Evidence for safety and efficacy of DOTAP cationic liposome mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis.

Authors:  D J Porteous; J R Dorin; G McLachlan; H Davidson-Smith; H Davidson; B J Stevenson; A D Carothers; W A Wallace; S Moralee; C Hoenes; G Kallmeyer; U Michaelis; K Naujoks; L P Ho; J M Samways; M Imrie; A P Greening; J A Innes
Journal:  Gene Ther       Date:  1997-03       Impact factor: 5.250

Review 3.  Role of airway surface liquid and submucosal glands in cystic fibrosis lung disease.

Authors:  A S Verkman; Yuanlin Song; Jay R Thiagarajah
Journal:  Am J Physiol Cell Physiol       Date:  2003-01       Impact factor: 4.249

4.  Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA.

Authors:  J R Riordan; J M Rommens; B Kerem; N Alon; R Rozmahel; Z Grzelczak; J Zielenski; S Lok; N Plavsic; J L Chou
Journal:  Science       Date:  1989-09-08       Impact factor: 47.728

5.  A phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF using maxillary sinus delivery in patients with cystic fibrosis with antrostomies.

Authors:  John A Wagner; Ilynn B Nepomuceno; Anna H Messner; Mary Lynn Moran; Eric P Batson; Sue Dimiceli; Byron W Brown; Julie K Desch; Alexander M Norbash; Carol K Conrad; William B Guggino; Terence R Flotte; Jeffrey J Wine; Barrie J Carter; Thomas C Reynolds; Richard B Moss; Phyllis Gardner
Journal:  Hum Gene Ther       Date:  2002-07-20       Impact factor: 5.695

6.  In vivo nasal potential difference: techniques and protocols for assessing efficacy of gene transfer in cystic fibrosis.

Authors:  M R Knowles; A M Paradiso; R C Boucher
Journal:  Hum Gene Ther       Date:  1995-04       Impact factor: 5.695

Review 7.  Physiological basis of cystic fibrosis: a historical perspective.

Authors:  P M Quinton
Journal:  Physiol Rev       Date:  1999-01       Impact factor: 37.312

8.  Cellular localization and activity of Ad-delivered GFP-CFTR in airway epithelial and tracheal cells.

Authors:  Ophélia Granio; Caroline Norez; Katherine J D Ashbourne Excoffon; Philip H Karp; Monika Lusky; Frédéric Becq; Pierre Boulanger; Joseph Zabner; Saw-See Hong
Journal:  Am J Respir Cell Mol Biol       Date:  2007-07-19       Impact factor: 6.914

9.  Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled phase 2B trial.

Authors:  Richard B Moss; Carlos Milla; John Colombo; Frank Accurso; Pamela L Zeitlin; John P Clancy; L Terry Spencer; Joseph Pilewski; David A Waltz; Henry L Dorkin; Thomas Ferkol; Mark Pian; Bonnie Ramsey; Barrie J Carter; Dana B Martin; Alison E Heald
Journal:  Hum Gene Ther       Date:  2007-08       Impact factor: 5.695

10.  CFTR delivery to 25% of surface epithelial cells restores normal rates of mucus transport to human cystic fibrosis airway epithelium.

Authors:  Liqun Zhang; Brian Button; Sherif E Gabriel; Susan Burkett; Yu Yan; Mario H Skiadopoulos; Yan Li Dang; Leatrice N Vogel; Tristan McKay; April Mengos; Richard C Boucher; Peter L Collins; Raymond J Pickles
Journal:  PLoS Biol       Date:  2009-07-21       Impact factor: 8.029

View more
  12 in total

Review 1.  Genome editing revolutionize the creation of genetically modified pigs for modeling human diseases.

Authors:  Jing Yao; Jiaojiao Huang; Jianguo Zhao
Journal:  Hum Genet       Date:  2016-07-18       Impact factor: 4.132

2.  Restoration of CFTR Activity in Ducts Rescues Acinar Cell Function and Reduces Inflammation in Pancreatic and Salivary Glands of Mice.

Authors:  Mei Zeng; Mitchell Szymczak; Malini Ahuja; Changyu Zheng; Hongen Yin; William Swaim; John A Chiorini; Robert J Bridges; Shmuel Muallem
Journal:  Gastroenterology       Date:  2017-06-19       Impact factor: 22.682

3.  Partial Restoration of CFTR Function in cftr-Null Mice following Targeted Cell Replacement Therapy.

Authors:  Pascal Duchesneau; Rickvinder Besla; Mathieu F Derouet; Li Guo; Golnaz Karoubi; Amanda Silberberg; Amy P Wong; Thomas K Waddell
Journal:  Mol Ther       Date:  2017-02-08       Impact factor: 11.454

Review 4.  New insights into the pathogenesis of cystic fibrosis sinusitis.

Authors:  Eugene H Chang
Journal:  Int Forum Allergy Rhinol       Date:  2013-11-26       Impact factor: 3.858

Review 5.  Contemporary Animal Models For Human Gene Therapy Applications.

Authors:  Chitra Gopinath; Trupti Job Nathar; Arkasubhra Ghosh; Dennis Durand Hickstein; Everette Jacob Remington Nelson
Journal:  Curr Gene Ther       Date:  2015       Impact factor: 4.391

Review 6.  Lessons learned from the cystic fibrosis pig.

Authors:  David K Meyerholz
Journal:  Theriogenology       Date:  2016-04-21       Impact factor: 2.740

7.  Lentiviral-mediated phenotypic correction of cystic fibrosis pigs.

Authors:  Ashley L Cooney; Mahmoud H Abou Alaiwa; Viral S Shah; Drake C Bouzek; Mallory R Stroik; Linda S Powers; Nick D Gansemer; David K Meyerholz; Michael J Welsh; David A Stoltz; Patrick L Sinn; Paul B McCray
Journal:  JCI Insight       Date:  2016-09-08

8.  Porcine nasal epithelial cultures for studies of cystic fibrosis sinusitis.

Authors:  Nichole Dean; Neel K Ranganath; Brandon Jones; Shaoyan Zhang; Daniel Skinner; Steven M Rowe; Eric J Sorscher; Bradford A Woodworth
Journal:  Int Forum Allergy Rhinol       Date:  2014-04-14       Impact factor: 3.858

9.  Relationships among CFTR expression, HCO3- secretion, and host defense may inform gene- and cell-based cystic fibrosis therapies.

Authors:  Viral S Shah; Sarah Ernst; Xiao Xiao Tang; Philip H Karp; Connor P Parker; Lynda S Ostedgaard; Michael J Welsh
Journal:  Proc Natl Acad Sci U S A       Date:  2016-04-25       Impact factor: 11.205

Review 10.  Cystic Fibrosis Gene Therapy in the UK and Elsewhere.

Authors:  Uta Griesenbach; Kamila M Pytel; Eric W F W Alton
Journal:  Hum Gene Ther       Date:  2015-05       Impact factor: 5.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.